Keywords: Pfizer, Figitumumab, NSCLC, Prevnar 13, Basilea, Johnson & Johnson, Ceftobiprole, FDA

Pfizer drops figitumumab in NSCLC on disappointing Ph III; FDA delays Prevnar 13 and rejects Basilea/J&J’s ceftobiprole for cSSSI

Article | 04 January 2010

Print This

Global drug behemoth Pfizer has discontinued the development of A4021016 (also known as ADVIGO 1016), in a Phase III trial examining ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in